LuX-Valve Plus in China: Tricuspid Heart Valve Assessment
Direct Answer: What LuX-Valve Plus Is and What “Assessment in China” Actually Means
LuX-Valve Plus is a transcatheter tricuspid valve replacement device developed by Jenscare, a China-based medical device manufacturer. According to the manufacturer’s own product information, it is delivered through transvascular access and is designed to replace the tricuspid valve rather than clip its leaflets. That single design distinction matters when you are reading about tricuspid procedures, because “transcatheter tricuspid” describes a broad family of approaches, not one interchangeable treatment.
For a patient or family researching LuX-Valve Plus China access, the practical question is not whether the device exists. It is whether an individual heart is a candidate, and whether a specific center can confirm in writing that it can evaluate and, if appropriate, treat that person. Those are two separate questions, and neither can be answered from a website page. Assessment in China means a records-based review followed by center-specific confirmation — not a booking, not a price list, and not a promise of treatment.
What the Manufacturer States About the Device
Transvascular replacement, not leaflet clipping
Jenscare describes LuX-Valve Plus as a transcatheter tricuspid valve replacement system using transvascular access. The manufacturer states that the device replaces the valve rather than clipping leaflets. This is a design description from the company that makes the product. It should be read as manufacturer information, not as independent comparative evidence showing that one approach is better than another for any particular patient.
EU MDR CE certification announced 23 July 2026
The manufacturer announced EU MDR CE certification for LuX-Valve Plus on 23 July 2026. Several careful conclusions follow from that announcement, and several do not.
- It is not accurate to describe the device as existing only in China.
- It is not accurate to say that all European hospitals offer it. Certification is a regulatory milestone, not a statement about which hospitals stock, train for, or perform any given procedure.
- EU certification does not establish UK or US approval, and it does not by itself tell you anything about eligibility for an individual patient.
Because approval status and availability differ by country and change over time, the only reliable answer for your situation comes from the center you are actually asking. Confirm current status directly rather than relying on any general article, including this one.
Why the Tricuspid Valve Is Difficult to Assess From Symptoms Alone
Tricuspid regurgitation is leakage between the right atrium and the right ventricle. The Cleveland Clinic explains that underlying heart disease, atrial enlargement, or implanted-device leads can be involved. That list is the reason a symptom-first approach fails: breathlessness, swelling, fatigue, or a racing sensation can arise from several different mechanisms, and the same symptom can point to different causes in different people.
Symptoms alone do not establish the cause of tricuspid regurgitation. Clinical imaging and specialist evaluation guide management, which may include medication, repair, or replacement. Note the word “may.” None of those options is automatic, and none is ruled in or out by a web search. A device such as LuX-Valve Plus sits inside one branch of that decision tree — replacement — and only a specialist evaluation using the person’s own imaging and history can say whether that branch is relevant.
One common misunderstanding is worth naming directly: the presence of an implanted lead does not mean the lead must be extracted, and it does not mean a replacement device is recommended. The Cleveland Clinic lists implanted-device leads among possible contributing factors. It does not state an automatic consequence. Anyone who tells you otherwise is going beyond the evidence.
What a Records-Based Assessment Typically Involves
Because tricuspid evaluation depends on imaging and specialist judgment, the useful first step is assembling records, not choosing a procedure. A center reviewing an overseas enquiry generally needs enough information to judge whether it can help at all. Typical components include:
- Recent cardiac imaging reports, including the echocardiographic assessment of the tricuspid valve and right heart.
- Reports from any prior cardiac procedures or implanted devices, with relevant documentation.
- Current medication list and relevant history of heart disease or rhythm problems.
- Recent specialist consultation notes, if available.
This is a description of the kind of material a review draws on, not a self-selection checklist and not a substitute for medical advice. You do not need to decide in advance whether you “qualify.” That determination belongs to the evaluating clinicians, based on the actual records.
Two practical points follow. First, imaging performed elsewhere may or may not be sufficient for a given center’s review; ask what they require rather than assuming. Second, records review and a formal clinical assessment are different stages. A records review can tell you whether a center is willing to proceed to evaluation. It cannot tell you the outcome of that evaluation.
Questions to Ask Before Relying on Any Arrangement
The following are questions, not facts. Each one should be answered in writing by the specific center involved, because arrangements vary by hospital and by case.
- Does this center currently evaluate patients for transcatheter tricuspid valve replacement, and is LuX-Valve Plus among the options it can discuss?
- What records and imaging does the center require before it will schedule an evaluation?
- Who performs the specialist evaluation, and what does that evaluation involve?
- What is the current regulatory and availability status of the device at this center?
- What costs apply, how and when are they billed, and what is excluded?
- What language support is available for records, consent, and consultations?
- What follow-up is expected after any procedure, and can it be coordinated with my cardiologist at home?
- What happens if the evaluation concludes that this device is not appropriate for me?
If any of these cannot be answered clearly and in writing, treat that as information in itself. Vague assurances about availability, eligibility, or cost are not confirmation.
Where China Medical Services Fits
China Medical Services is a non-clinical care coordinator. We do not diagnose, we do not determine eligibility, and we do not provide clinical advice. Our role is practical: helping organize records, clarifying what a center has asked for, and supporting communication so that questions reach the people who can actually answer them. Any hospital arrangement or access requires case-specific written confirmation, and we do not guarantee appointments, outcomes, or timelines.
If you would like help preparing records and framing questions for a center, you can start here: companion support. General information about our services is at chinamedservices.com.
FAQ
Is LuX-Valve Plus the same as a tricuspid clip?
No. The manufacturer describes LuX-Valve Plus as replacing the tricuspid valve rather than clipping its leaflets. Clipping and replacement are different approaches, and the choice between approaches, if any, is a specialist decision based on individual imaging and history.
Does EU CE certification mean the device is available everywhere in Europe?
No. The manufacturer announced EU MDR CE certification on 23 July 2026. Certification is a regulatory milestone; it does not mean every hospital offers the device, and it does not establish UK or US approval.
Can I find out from a website whether I am eligible?
No. Eligibility depends on clinical imaging and specialist evaluation of your own records. Symptoms alone do not establish the cause of tricuspid regurgitation, and no article can substitute for that evaluation.
Does having a pacemaker or other implanted lead mean I need it removed?
No. Implanted-device leads are listed among possible contributing factors in tricuspid regurgitation. That is not the same as a recommendation for lead extraction, and no automatic conclusion should be drawn.
Can China Medical Services confirm a hospital will accept my case?
No. We are a non-clinical coordinator. Confirmation of evaluation, availability, and arrangements must come in writing from the specific center, on a case-by-case basis.
References
- Jenscare: LuX-Valve Plus product information — https://en.jenscare.com/product/180.html
- Jenscare: LuX-Valve Plus receives EU MDR CE certification — https://en.jenscare.com/new/424.html
- Cleveland Clinic: Tricuspid valve regurgitation — https://my.clevelandclinic.org/health/diseases/21627-tricuspid-valve-regurgitation
General information for care planning, not a diagnosis or personal treatment recommendation. Clinical decisions belong to qualified treating professionals.
